PT2041129E - Inibidores de proteína tirosina fosfatase humana e a sua utilização farmacêutica - Google Patents

Inibidores de proteína tirosina fosfatase humana e a sua utilização farmacêutica Download PDF

Info

Publication number
PT2041129E
PT2041129E PT78099090T PT07809909T PT2041129E PT 2041129 E PT2041129 E PT 2041129E PT 78099090 T PT78099090 T PT 78099090T PT 07809909 T PT07809909 T PT 07809909T PT 2041129 E PT2041129 E PT 2041129E
Authority
PT
Portugal
Prior art keywords
human protein
pharmaceutical use
tyrosine phosphatase
phosphatase inhibitors
inhibitors
Prior art date
Application number
PT78099090T
Other languages
English (en)
Inventor
Jeffrey Lyle Gray
Cynthia Monesa Clark
Kande Amarasinghe
Mathew Brian Maier
Ryan Nichols
Original Assignee
Aerpio Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38704718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2041129(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aerpio Therapeutics Inc filed Critical Aerpio Therapeutics Inc
Publication of PT2041129E publication Critical patent/PT2041129E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT78099090T 2006-06-27 2007-06-27 Inibidores de proteína tirosina fosfatase humana e a sua utilização farmacêutica PT2041129E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81682506P 2006-06-27 2006-06-27

Publications (1)

Publication Number Publication Date
PT2041129E true PT2041129E (pt) 2014-10-08

Family

ID=38704718

Family Applications (2)

Application Number Title Priority Date Filing Date
PT78099090T PT2041129E (pt) 2006-06-27 2007-06-27 Inibidores de proteína tirosina fosfatase humana e a sua utilização farmacêutica
PT141661215T PT2803663T (pt) 2006-06-27 2007-06-27 Inibidores de proteína tirosina fosfatase humana e a sua utilização farmacêutica

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT141661215T PT2803663T (pt) 2006-06-27 2007-06-27 Inibidores de proteína tirosina fosfatase humana e a sua utilização farmacêutica

Country Status (23)

Country Link
US (3) US7589212B2 (pt)
EP (3) EP2803663B1 (pt)
JP (1) JP5201740B2 (pt)
KR (1) KR101157844B1 (pt)
CN (1) CN101506204B (pt)
AU (1) AU2007265455B2 (pt)
BR (1) BRPI0713349A2 (pt)
CA (1) CA2656915C (pt)
CO (1) CO6150143A2 (pt)
CY (1) CY1115588T1 (pt)
DK (2) DK2803663T3 (pt)
ES (2) ES2660571T3 (pt)
HK (2) HK1129388A1 (pt)
IL (1) IL196130A (pt)
MX (1) MX2009000290A (pt)
NZ (1) NZ574405A (pt)
PL (2) PL2041129T3 (pt)
PT (2) PT2041129E (pt)
RU (1) RU2430101C2 (pt)
SI (1) SI2041129T1 (pt)
TR (1) TR201802280T4 (pt)
WO (1) WO2008002571A2 (pt)
ZA (1) ZA200900558B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507568B2 (en) * 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US7226755B1 (en) * 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
DK2371865T3 (en) 2006-04-07 2017-10-23 Aerpio Therapeutics Inc Antibodies that bind human protein tyrosine phosphatase beta (HPTP-β) and uses thereof
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) * 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) * 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) * 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
RU2014146121A (ru) * 2009-01-12 2015-06-10 Аэрпио Терапьютикс Инк. Способы лечения синдрома сосудистой утечки
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
AU2014202211B2 (en) * 2009-01-12 2016-06-02 EyePoint Pharmaceuticals, Inc. Methods for treating vascular leak syndrome
AU2016203254B2 (en) * 2009-01-12 2018-09-13 EyePoint Pharmaceuticals, Inc. Methods for treating vascular leak syndrome
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
CN103976998A (zh) 2009-07-06 2014-08-13 爱尔皮奥治疗有限公司 用于防止癌细胞转移的化合物、组合物和方法
MX2012005273A (es) 2009-11-06 2012-06-19 Aerpio Therapeutics Inc Metodos para incrementar la estabilizacion de factor-1 alfa inducible por hipoxia.
US20120129847A1 (en) * 2010-10-07 2012-05-24 Kevin Gene Peters Compositions and methods for treating ocular edema, neovascularization and related diseases
AU2012323856B2 (en) 2011-10-13 2017-05-25 EyePoint Pharmaceuticals, Inc. Methods for treating Vascular Leak Syndrome and cancer
AU2012323849B2 (en) 2011-10-13 2017-04-20 EyePoint Pharmaceuticals, Inc. Treatment of ocular disease
RU2507597C2 (ru) * 2012-05-23 2014-02-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Способ фармакологической коррекции ишемии скелетной мышцы никорандилом
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
MY171945A (en) 2013-03-15 2019-11-08 Aerpio Therapeutics Inc Compositions, formulations and methods for treating ocular diseases
RU2526466C1 (ru) * 2013-04-04 2014-08-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" Сибирского отделения Российской академии медицинских наук Средство для стимуляции васкуляризации сердечной мышцы при постинфарктном ее ремоделировании в эксперименте
EP3107542B1 (en) 2014-02-19 2019-05-01 Aerpio Therapeutics, Inc. Process for preparing n-benzyl-3-hydroxy-4-substituted-pyridin-2-(1h)-ones
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
WO2016022813A1 (en) 2014-08-07 2016-02-11 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of tie-2
WO2017053566A1 (en) 2015-09-23 2017-03-30 Aerpio Therapeutics, Inc. Methods of treating intraocular pressure with activators of tie-2
KR20190031246A (ko) 2016-07-20 2019-03-25 에르피오 세러퓨틱스 인코포레이티드 VE-PTP (HPTP-β)를 표적으로 하는 인간화된 단클론성 항체
CN109996440A (zh) * 2016-10-21 2019-07-09 曼宁研究有限公司 Ve-ptp敲除
US10900319B2 (en) 2017-12-14 2021-01-26 Exacta-Frac Energy Services, Inc. Cased bore straddle packer
CN113164597A (zh) 2018-09-24 2021-07-23 爱尔皮奥制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
CN114269341A (zh) 2019-04-29 2022-04-01 视点制药公司 靶向施莱姆管的Tie-2激活剂
GB2589400A (en) 2019-06-24 2021-06-02 Aerpio Pharmaceuticals Inc Formulations of tie-2 activators and methods of use thereof
CA3156225A1 (en) 2019-10-29 2021-05-06 EyePoint Pharmaceuticals, Inc. Small molecule activators of tie-2
CN117343052B (zh) * 2023-12-04 2024-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673641A (en) 1982-12-16 1987-06-16 Molecular Genetics Research And Development Limited Partnership Co-aggregate purification of proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69332197T2 (de) 1992-03-13 2003-04-17 Organon Teknika Bv Epstein-Barr-Virus verwandte Peptide und Nukleinsäuresegmenten
EP0642353A1 (en) * 1992-05-14 1995-03-15 Oncologix, Inc. Treatment of vascular leakage syndrome and collagenase induced disease by administration of matrix metalloproteinase inhibitors
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
US5688781A (en) * 1994-08-19 1997-11-18 Bristol-Myers Squibb Company Method for treating vascular leak syndrome
EP0833934B2 (en) 1995-06-15 2012-08-15 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
JPH106346A (ja) * 1996-06-19 1998-01-13 Takemoto Oil & Fat Co Ltd プラスチック成形型の製造方法及びプラスチック成形型
AR022303A1 (es) * 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
EP1046715A1 (en) 1999-04-23 2000-10-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2
WO2000065088A2 (en) 1999-04-26 2000-11-02 Amersham Pharmacia Biotech Ab Primers for identifying typing or classifying nucleic acids
US6342219B1 (en) 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
WO2000070030A1 (en) 1999-05-19 2000-11-23 Amgen Inc. Crystal of a lymphocyte kinase-ligand complex and methods of use
AU775625B2 (en) 1999-08-27 2004-08-05 Sugen, Inc. Phosphate mimics and methods of treatment using phosphatase inhibitors
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
RU2246501C2 (ru) 2000-09-27 2005-02-20 Дзе Проктер Энд Гэмбл Компани Лиганды меланокортиновых рецепторов
AU2003222127A1 (en) * 2002-03-29 2003-10-13 Ontogen Corporation Sulfamic acids as inhibitors of human cytoplasmic protein tyrosine phosphatases
US7507568B2 (en) 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US7226755B1 (en) 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
US20050154011A1 (en) 2003-02-20 2005-07-14 The Procter & Gamble Company Tetrahydroisoquinolnyl sulfamic acids
US20040242676A1 (en) * 2003-05-30 2004-12-02 Alessi Thomas R. Method of mitigating the adverse effects of IL-2
WO2005027183A2 (en) * 2003-09-17 2005-03-24 Koninklijke Philips Electronics N.V. High intensity discharge lamp
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
DK2371865T3 (en) 2006-04-07 2017-10-23 Aerpio Therapeutics Inc Antibodies that bind human protein tyrosine phosphatase beta (HPTP-β) and uses thereof
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) * 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
CN103976998A (zh) 2009-07-06 2014-08-13 爱尔皮奥治疗有限公司 用于防止癌细胞转移的化合物、组合物和方法

Also Published As

Publication number Publication date
CY1115588T1 (el) 2017-01-04
ES2510674T3 (es) 2014-10-21
US20090227639A1 (en) 2009-09-10
DK2803663T3 (en) 2018-03-05
NZ574405A (en) 2012-01-12
EP2041129A2 (en) 2009-04-01
US8338615B2 (en) 2012-12-25
EP2803663A1 (en) 2014-11-19
HK1203960A1 (en) 2015-11-06
RU2430101C2 (ru) 2011-09-27
PL2803663T3 (pl) 2018-05-30
IL196130A0 (en) 2009-09-22
KR20090024296A (ko) 2009-03-06
CO6150143A2 (es) 2010-04-20
CN101506204B (zh) 2012-05-30
US7589212B2 (en) 2009-09-15
US20120077853A1 (en) 2012-03-29
MX2009000290A (es) 2009-03-16
CA2656915C (en) 2012-08-07
DK2041129T3 (da) 2014-10-13
JP5201740B2 (ja) 2013-06-05
RU2009102537A (ru) 2010-08-10
PT2803663T (pt) 2018-02-28
CN101506204A (zh) 2009-08-12
BRPI0713349A2 (pt) 2012-03-06
US20070299116A1 (en) 2007-12-27
SI2041129T1 (sl) 2014-11-28
EP2803663B1 (en) 2017-11-29
JP2009542660A (ja) 2009-12-03
IL196130A (en) 2014-04-30
AU2007265455A2 (en) 2009-05-21
AU2007265455B2 (en) 2011-11-10
EP2041129B1 (en) 2014-09-03
PL2041129T3 (pl) 2014-11-28
US8188125B2 (en) 2012-05-29
HK1129388A1 (en) 2009-11-27
KR101157844B1 (ko) 2012-06-22
WO2008002571A3 (en) 2008-02-14
EP3287455A1 (en) 2018-02-28
ES2660571T3 (es) 2018-03-23
WO2008002571A2 (en) 2008-01-03
TR201802280T4 (tr) 2018-03-21
CA2656915A1 (en) 2008-01-03
AU2007265455A1 (en) 2008-01-03
WO2008002571B1 (en) 2008-04-17
ZA200900558B (en) 2012-04-24

Similar Documents

Publication Publication Date Title
HK1129388A1 (en) Human protein-tyrosine phosphatase inhibitors and their pharmaceutical use
SI2038265T1 (sl) Inhibitorji človeške protein-tirozin-fosfataze in postopki uporabe
PL2592072T3 (pl) Inhibitory ludzkiej białkowej fosfatazy tyrozynowej i ich zastosowanie
GB0625659D0 (en) Therapeutic compounds and their use
IL242883B (en) Aryl-amino and heteroaryl-amino converted deoxazolines and pharmaceutical preparations containing them
ZA200902084B (en) Combination therapy with SGLT-2 inhibitors and their pharmaceutical compositions
EP2046413A4 (en) MEDICAL SYSTEMS AND APPLICATION METHOD
HK1136160A1 (en) Disintegrin variants and pharmaceutical uses thereof
IL198893A0 (en) Lipase variants for pharmaceutical use
IL195161A0 (en) Pharmaceutical compositions of ropinirole and methods of use thereof
IL204442A (en) Inhibitors of atpase-0fif, medicinal preparations containing them and their use
PL2036882T3 (pl) Związki o jonach obojnaczych i ich zastosowanie
IL194751A0 (en) Drugs and uses
EP2224928A4 (en) NOVEL INHIBITORS OF SEH AND THEIR USE
GB2443336B (en) Spiruchostatin analogues and their medicinal use
GB0516069D0 (en) Pharmaceutical and use thereof
HK1141211A1 (en) Novel seh inhibitors and their use
EP2217068A4 (en) NOVEL INHIBITORS OF SEH AND THEIR USE
EP2209376A4 (en) NEW SEH-HEMMER AND ITS USE
PL2012805T3 (pl) Kompozycja lecznicza i jej zastosowanie
GB0614365D0 (en) Pharmaceutical compositions and their use
EP2097378A4 (en) NOVEL INHIBITORS OF SEH AND USE THEREOF
GB0614538D0 (en) Therapeutic Compounds And Their Use
GB0625633D0 (en) Therapeutic compounds and their use
HU0600403D0 (en) New pharmaceutical intermediates and their use